市场调查报告书
商品编码
1618262
医疗用线粒子加速器:市场洞察·竞争环境·市场预测 (~2030年)Medical Linear Particle Accelerator - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
医疗直线粒子加速器市场规模预计将从 2023 年的 25.6 亿美元增长到 2030 年的 33.9 亿美元,预测期内复合年增长率为 4.79%。 由于各种癌症盛行率的增加、产品开发活动的增加以及各种医用线性粒子加速器的可用性等因素,医用线性粒子加速器市场正在显着增长。
医用直线粒子加速器:市场动态
根据世界卫生组织(WHO)2024年提供的数据,国际癌症研究机构(IARC)表示,2022年全球新增癌症病例达2,000万例。据同一消息来源称,在登记的新癌症病例中,全球新增肺癌病例达250万例,成为最常见的癌症。其次是乳癌(230万例)、大肠癌(190万例)和胃癌(97万例)。
随着癌症发生率的上升,医疗保健系统正在寻求有效且精确的放射治疗方案,以满足不同地区不断增长的患者需求,从而推动市场成长。
按治疗类型划分,影像导引放射治疗领域将在 2023 年占据显着的收入占有率。这是由于其在治疗复杂癌症方面的高精度和适应性。
该技术整合了高解析度成像和放射传输,使临床医生能够即时可视化肿瘤和周围的解剖结构。这种能力对于准确定位肿瘤至关重要,特别是那些位于移动区域或靠近敏感结构(例如肺部或腹部)的肿瘤。
本报告提供全球医疗用线粒子加速器的市场调查,彙整市场概要,市场影响因素及市场机会分析,法律制度,市场规模的转变·预测,各种区分·地区/各主要国家的详细分析,竞争情形,主要企业简介等资讯。
Medical linear particle accelerator market by Product Type (Dedicated Linear Accelerator and Non-Dedicated Linear Accelerator), Treatment Type (Intensity Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, Image Guided Radiation Therapy, and Stereotactic Radiosurgery/Stereotactic Body Radiotherapy), End-User (Hospital, Radiology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing instances of cancers and the rising product developmental activities across the globe
The medical linear particle accelerator market was valued at USD 2.56 billion in 2023, growing at a CAGR of 4.79% during the forecast period from 2024 to 2030 to reach USD 3.39 billion by 2030. The medical linear particle accelerator market is experiencing significant growth due to the increasing cases of different types of cancers among the population, rising product developmental activities, and the availability of a wide variety of medical linear particle accelerators acting as major factors contributing to the overall growth of the medical linear particle accelerator market during the forecast period from 2024 to 2030.
Medical Linear Particle Accelerator Market Dynamics:
According to data provided by the World Health Organization in 2024, the International Agency for Research on Cancer (IARC) stated that 20 million new instances of cancer were registered in 2022 globally. As per the same source, lung cancer accounted for 2.5 million new cases globally, of all the registered new cancer cases, making it the most common cancer. Next in order of incidence was breast cancer with 2.3 million cases, colon cancer with 1.9 million cases, and stomach cancer with 0.97 million cases globally.
The Global Cancer Observatory (2024), estimated that the new instances of cancer globally would reach from 20 million to 24.1 million by 2030. It stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases.
As cancer rates climb, healthcare systems seek effective, precise radiation treatment options, fueling medical linear particle accelerators market growth to meet expanding patient needs across diverse regions.
Various product developmental activities by key market players will further boost the market for the same. For instance, in May 2024, Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high-definition AI-enhanced imaging, capable of delivering offline and online adaptive radiation therapy as well as improved standard image-guided radiation therapy treatments. This highly versatile CT-Linac will enable clinicians to choose the most suitable radiation therapy technique for each patient.
Hence, the interplay of all the above-mentioned factors are expected to drive the medical linear particle accelerator market during the given forecast period from 2024 to 2030.
However, the dearth of skilled specialists for equipment operation and handling, potential risks associated with medical linear particle accelerators, and others may restrict the market growth for the medical linear particle accelerator market.
Medical Linear Particle Accelerator Market Segment Analysis:
Medical linear particle accelerator market by Product Type (Dedicated Linear Accelerator and Non-Dedicated Linear Accelerator), Treatment Type (Intensity Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, Image Guided Radiation Therapy, and Stereotactic Radiosurgery/Stereotactic Body Radiotherapy), End-User (Hospital, Radiology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the treatment type segment of the medical linear particle accelerator market, the image-guided radiation therapy category is expected to have a significant revenue share in the year 2023. This is due to its high precision and adaptability in treating complex cancers.
This technology integrates high-resolution imaging with radiation delivery, allowing clinicians to visualize the tumor and surrounding anatomy in real-time. This capability is crucial for accurately targeting tumors, especially in areas where movement occurs, such as the lungs or abdomen, as well as for tumors located near sensitive structures.
Real-time imaging allows clinicians to adjust the radiation beam during treatment, adapting to changes in tumor position or size between sessions, a feature known as adaptive radiotherapy. By sparing healthy tissues and delivering radiation precisely to the tumor site, image guided radiation therapy reduces side effects and improves treatment efficacy.
Additionally, in March 2023, GenesisCare, one of the leading integrated cancer care providers, launched ViewRay's advanced MRIdian MRI-guided radiation therapy system. Providing access to the precision of MRIdian Stereotactic MRI-guided Adaptive Radiotherapy (SMART) therapy in a community cancer care setting may help reduce the burden of cancer treatment for patients who choose GenesisCare.
Therefore, the widespread uses and various advantages of image-guided radiation therapy category enhance performance and usability, solidifying a significant impact on the growth of the overall medical linear particle accelerator market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall medical linear particle accelerator market:
Among all the regions, North America is estimated to hold a significant revenue share in the medical linear particle accelerator market. This can be attributed to several factors such as the rising cancer cases, and the continuous advancements in this field, which offers improved treatment features and efficiency, which are the major key factors that contribute to the growth of the medical linear particle accelerator market in the North America region during the forecast period from 2024 to 2030.
National Cancer Institute (2024) estimated that 2 million new cases of cancer will be diagnosed in the US by the end of 2024. Furthermore, it is estimated that prostate, lung, and colorectal cancers are expected to represent approximately 48% of all cancer diagnoses in men. For women, the most prevalent cancers are breast, lung, and colorectal, which are expected to account for about 51% of all new cancer diagnoses.
According to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases and Canada represented 10.9% of all cancer cases in the region.
With the US expected to account for a substantial proportion of these cancer cases, healthcare providers are compelled to enhance their cancer treatment capabilities, leading to greater investment in advanced medical linear particle accelerators. This growing patient population necessitates innovative and effective treatment options, thereby expanding the market for the same.
Various product developmental strategies such as clearances in the region by regulatory authorities in the region play a major role in pushing forward the revenue shares of medical linear particle accelerators in the region. For example, in October 2021, Panacea Medical Technologies, one of the world-leading manufacturers of advanced Radiation Oncology and Radiology equipment, received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation Stereotactic Body Radiotherapy (SBRT) enabled Linear Accelerator on a ring gantry platform.
Moreover, product launches by key market players in the region are further expected to propel the growth of the North America medical linear particle accelerator market.
Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the medical linear particle accelerator market during the forecast period from 2024 to 2030.
Medical Linear Particle Accelerator Market key players:
Some of the key market players operating in the Medical Linear Particle Accelerator market include Elekta, Accuray Incorporated, SHINVA MEDICAL INSTRUMENT CO., LTD., VIEWRAY TECHNOLOGIES, INC., Altair Technologies, Inc., AccSys Technology, Inc., S.I.T. Sordina IORT Technologies S.p.A., Siemens Healthcare GmbH, Brainlab AG, Panacea Medical Technologies Pvt. Ltd., MITSUBISHI HEAVY INDUSTRIES, LTD., and others.
Recent Developmental Activities in the Medical Linear Particle Accelerator Market:
Key takeaways from the Medical Linear Particle Accelerator market report study
Target audience who can be benefited from this Medical Linear Particle Accelerator market report study
Frequently Asked Questions for the Medical Linear Particle Accelerator Market: